90887
document
The effects of the angiotensin-converting enzyme inhibitor imidapril on plasma plasminogen activator inhibitor activity in patients with acute myocardial infarction . This study sought to determine whether early treatment with angiotensin-converting enzyme ( ACE ) inhibitors in patients with acute myocardial infarction ( AMI ) is useful for the improvement of fibrinolytic function , as well as left ventricular function . This study was designed to examine the levels of plasma plasminogen activator inhibitor ( PAI ) activity and serum ACE activity during the course of 2 weeks in 40 patients with AMI within 12 hours after the onset of the symptom and who randomly received early treatment with either the ACE inhibitor imidapril or a placebo ( 20 patients in the imidapril group and 20 in the placebo group ) . The levels of serum ACE activity in the imidapril group decreased significantly ( p < 0.01 ) 8 hours after the administration of imidapril , and the levels 24 hours after administration were significantly lower than those in the placebo group ( 3.6 +/- 0.6 IU/L vs 7.4 +/- 0.8 IU/L ; p < 0.001 ) . The plasma PAI activity increased gradually to peak levels 16 hours after the administration of imidapril and placebo . The levels in the placebo group decreased gradually but remained high during the study period . On the other hand , the levels of PAI activity in the imidapril group decreased rapidly and those 48 hours after administration were significantly lower than those in the placebo group ( 7.9 +/- 1.9 IU/ml vs 18.4 +/- 3.5 IU/ml ; p < 0.01 ) . The levels of left ventricular ejection fraction about 2 weeks after admission were significantly higher in the imidapril group than in the placebo group ( 65.9 % +/- 2.5 % vs 49.1 % +/- 4.4 % ; p < 0.01 ) . This study showed that imidapril , an ACE inhibitor , might be useful for the improvement of fibrinolytic function and left ventricular function in the acute phase of myocardial infarction .
90888
Intervention_Pharmacological
angiotensin-converting enzyme inhibitor imidapril
90889
Intervention_Pharmacological
angiotensin-converting enzyme ( ACE ) inhibitors
90890
Intervention_Pharmacological
ACE inhibitor imidapril
90891
Intervention_Control
placebo
90892
Intervention_Pharmacological
imidapril
90893
Intervention_Pharmacological
imidapril
90894
Intervention_Control
placebo
90895
Intervention_Control
placebo
90896
Intervention_Pharmacological
imidapril
90897
Outcome_Physical
fibrinolytic function
90898
Outcome_Physical
left ventricular function
90899
Outcome_Physical
plasma plasminogen activator inhibitor ( PAI ) activity
90900
Outcome_Physical
serum ACE activity
90901
Outcome_Physical
levels of serum ACE activity
90902
Outcome_Physical
plasma PAI activity
90903
Outcome_Physical
levels of PAI activity
90904
Outcome_Physical
levels of left ventricular ejection fraction
90905
Outcome_Physical
fibrinolytic function
90906
Outcome_Physical
left ventricular function
90907
Participant_Condition
acute myocardial infarction
90908
Participant_Sample-size
40
90909
Participant_Condition
AMI
90910
Participant_Sample-size
20
90911
Participant_Sample-size
20